

SPECIAL H1N1 NOTICE: Message to Health Care providers regarding EUA for Peramivir IV

At the CDC's request, the Food and Drug Administration (FDA) recently issued an emergency use authorization (EUA) for the antiviral drug Peramivir IV for use in treating critically ill patients with 2009 H1N1.

The use of Peramivir under EUA is targeted to physicians in hospital settings managing patients who are severely ill and have not responded to other antivirals. It is also for patients for whom oral or inhalational antivirals cannot be administered or won't be readily absorbed. Providers must submit a request to the CDC to use Peramivir. This can be done electronically at <http://www.cdc.gov/h1n1flu/eua/peramivir.htm>. As part of the conditions of the EUA, healthcare providers must report adverse events and all medication errors to FDA's MedWatch program within 7 calendar days.

For more information visit the CDC's site at <http://www.cdc.gov/h1n1flu/eua/peramivir.htm> , the FDA's site at <http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm187814.htm> or visit the Healthcare - Clinicians section of <http://www.myflusafety.com/> . You can also call 1-800-CDC-INFO (1-800-232-4636) or send an email to: EUA.OCET@fda.hhs.gov.